Trending Now
Synthetic Biologics Inc (NYSE: SYN) adds an Exclusive License Option with...
Synthetic Biologics Inc (NYSE: SYN) is a diversified preclinical stage corporation that leverages microbiome functionality to develop medical therapies designed to treat and prevent GI...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Onconova Therapeutics Inc (NASDAQ:ONTX) Inducts Three Patients In The Phase 1...
Onconova Therapeutics Inc (NASDAQ:ONTX) announced three patients' recruitment by its partner - HanX Biopharmaceuticals, in the second cohort of Phase 1 clinical studies of...
MAKE IT MODERN
LATEST REVIEWS
CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc...
Sesen Bio Inc (NASDAQ:SESN) is pleased to announce the receipt of IND approval for its innovative drug – Vicineum, from CDE (Center...
MAKE IT MODERN
PERFORMANCE TRAINING
Vallon Pharmaceuticals Inc (VLON) stock could be just getting started
Vallon Pharmaceuticals, Inc. (VLON) closed on Friday at $0.4625 with a gain of $0.1945 or +72.57%. VLON didn't stop there and went...
Atossa Therapeutics Inc. (NASDAQ: ATOS) Receives Approval For Commencement Of Phase 2 Oral Endoxifen...
Atossa Therapeutics Inc. (NASDAQ: ATOS) has announced that the Swedish Ethics Review Authority has given it the approval to commence Phase 2 oral Endoxifen...
Nasdaq Listing Issues Anpac Bio-Medical Sciences Co Ltd (NASDAQ: ANPC) With a Written of...
AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) recently announced that the Nasdaq 100 (NDX-INDEX) issued it with a notice specifying that the company had...
EyePoint Pharmaceutical Inc. (NASDAQ:EYPT) Reports Revenue Of $15.7 Million In Q3 2020
EyePoint Pharmaceutical Inc. (NASDAQ:EYPT) has announced Q3 2020 financial results and provided its recent corporate development updates.
DEXYCU and YUTIQ net sales of $5.8 million
The...
Adaptimmune Therapeutics plc (NASDAQ: ADAP) Partner with Genentech to Develop and Commercialize Allogeneic Cell...
Cancer is one of the many devastating conditions across the globe which hundreds of households have had to live with due to lack of...
MAKE IT MODERN
